OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta

OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta
Magnify OSMR_HUMAN » Oncostatin-M-specific receptor subunit betaEnlarged view of image
3D view in GLMol or JMol

gray dot

Download Coordinates

gray dot

Topology in Plasma membrane
Topologyextracellular side
cytoplasmic side
OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta » Interleukin-31 receptor subunit beta;IL-31 receptor subunit beta; IL-31R subunit beta; IL-31R-beta; IL-31RB;
Hydrophobic Thickness 34.4 ± 1.2 Å
Tilt Angle 4 ± 3°
ΔGtransfer -28.3 kcal/mol
ΔGfold -20.3 kcal/mol
Links UniProtKB, Pfam, Interpro, iHOP, STRING, HGNC
Topology Out
TM Segments 738-762 (734-763)
Pathways

Cytokine-cytokine receptor interaction (KEGG)

Jak-STAT signaling pathway (KEGG)

PI3K-Akt signaling pathway (KEGG)

PDB none
OPM none
Complexes none
Interactions

ERBB2, Complex: ERBB2:OSMR, PubMed

IL6RB, Complex: IL6RB:OSMR, PubMed

Domains

AA: 525-609, PDBID: 1CN4, Subunit B, Seq Identity:32%, Fibronectin type III domain

UniProt annotation for OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta
FUNCTION: Associates with IL31RA to form the IL31 receptor. Binds IL31 to activate STAT3 and possibly STAT1 and STAT5. Capable of transducing OSM-specific signaling events.

SUBUNIT: Heterodimer composed of OSMR and IL6ST (type II OSM receptor). Heterodimer with IL31RA to form the IL31 receptor.

TISSUE SPECIFICITY: Expressed at relatively high levels in all neural cells as well as fibroblast, epithelial and a variety of tumor cell lines.

INDUCTION: Activated by oncostatin-M. Up-regulated by IFNG/IFN- gamma and bacterial lipopolysaccharides (LPS).

DOMAIN: The WSXWS motif appears to be necessary for proper protein folding and thereby efficient intracellular transport and cell- surface receptor binding.

DOMAIN: The box 1 motif is required for JAK interaction and/or activation.

DISEASE: Amyloidosis, primary localized cutaneous, 1 (PLCA1) OMIM: A primary amyloidosis characterized by localized cutaneous amyloid deposition. This condition usually presents with itching (especially on the lower legs) and visible changes of skin hyperpigmentation and thickening that may be exacerbated by chronic scratching and rubbing. Primary localized cutaneous amyloidosis is often divided into macular and lichen subtypes although many affected individuals often show both variants coexisting. Lichen amyloidosis characteristically presents as a pruritic eruption of grouped hyperkeratotic papules with a predilection for the shins, calves, ankles and dorsa of feet and thighs. Papules may coalesce to form hyperkeratotic plaques that can resemble lichen planus, lichen simplex or nodular prurigo. Macular amyloidosis is characterized by small pigmented macules that may merge to produce macular hyperpigmentation, sometimes with a reticulate or rippled pattern. In macular and lichen amyloidosis, amyloid is deposited in the papillary dermis in association with grouped colloid bodies, thought to represent degenerate basal keratinocytes. The amyloid deposits probably reflect a combination of degenerate keratin filaments, serum amyloid P component, and deposition of immunoglobulins. Note=The disease is caused by mutations affecting the gene represented in this entry.

UniProt features for OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta
SIGNAL 1 27 Potential.
CHAIN 28 979 Oncostatin-M-specific receptor subunit beta.
DOMAIN 332 424 Fibronectin type-III 1.
DOMAIN 430 524 Fibronectin type-III 2.
DOMAIN 526 619 Fibronectin type-III 3.
DOMAIN 625 732 Fibronectin type-III 4.
MOTIF 415 419 WSXWS motif.
MOTIF 770 778 Box 1 motif.
DISULFID 245 255 By similarity.
Amino Acid Sequence for OSMR_HUMAN » Oncostatin-M-specific receptor subunit beta
MALFAVFQTT FFLTLLSLRT YQSEVLAERL PLTPVSLKVS TNSTRQSLHL QWTVHNLPYH QELKMVFQIQ ISRIETSNVI WVGNYSTTVK WNQVLHWSWE SELPLECATH FVRIKSLVDD AKFPEPNFWS NWSSWEEVSV QDSTGQDILF VFPKDKLVEE GTNVTICYVS RNIQNNVSCY LEGKQIHGEQ LDPHVTAFNL NSVPFIRNKG TNIYCEASQG NVSEGMKGIV LFVSKVLEEP KDFSCETEDF KTLHCTWDPG TDTALGWSKQ PSQSYTLFES FSGEKKLCTH KNWCNWQITQ DSQETYNFTL IAENYLRKRS VNILFNLTHR VYLMNPFSVN FENVNATNAI MTWKVHSIRN NFTYLCQIEL HGEGKMMQYN VSIKVNGEYF LSELEPATEY MARVRCADAS HFWKWSEWSG QNFTTLEAAP SEAPDVWRIV SLEPGNHTVT LFWKPLSKLH ANGKILFYNV VVENLDKPSS SELHSIPAPA NSTKLILDRC SYQICVIANN SVGASPASVI VISADPENKE VEEERIAGTE GGFSLSWKPQ PGDVIGYVVD WCDHTQDVLG DFQWKNVGPN TTSTVISTDA FRPGVRYDFR IYGLSTKRIA CLLEKKTGYS QELAPSDNPH VLVDTLTSHS FTLSWKDYST ESQPGFIQGY HVYLKSKARQ CHPRFEKAVL SDGSECCKYK IDNPEEKALI VDNLKPESFY EFFITPFTSA GEGPSATFTK VTTPDEHSSM LIHILLPMVF CVLLIMVMCY LKSQWIKETC YPDIPDPYKS SILSLIKFKE NPHLIIMNVS DCIPDAIEVV SKPEGTKIQF LGTRKSLTET ELTKPNYLYL LPTEKNHSGP GPCICFENLT YNQAASDSGS CGHVPVSPKA PSMLGLMTSP ENVLKALEKN YMNSLGEIPA GETSLNYVSQ LASPMFGDKD SLPTNPVEAP HCSEYKMQMA VSLRLALPPP TENSSLSSIT LLDPGEHYC